BAXTER EXPECTS UP TO 50% ANNUAL INCREASE IN SALES TO AMERICAN HEALTHCARE SYSTEMS

BAXTER EXPECTS UP TO 50% ANNUAL INCREASE IN SALES TO AMERICAN HEALTHCARE SYSTEMS under a corporate agreement announced Aug. 9. Baxter currently does about $ 325 mil. a year in business with AmHS hospitals, primarily in I.V. products. While the new contract is the first corporate agreement between Baxter and AmHS, the hospital buying group signed a sole-source agreement with Baxter for I.V. products two years ago. The new agreement covers all of Baxter's divisions and products, and should increase Baxter's volume with AmHS to between $ 2.9 bil. and $ 6.4 bil. over the five and a half year course of the contract based on a projected 25-50% annual sales increase. The agreement takes effect in September. The contract calls for volume-based price discount incentives to encourage AmHS hospitals to participate. AmHS consists of 34 multi-hospital system shareholders, representing, in turn, approximately 1,050 hospitals and nursing homes. An AmHS spokesperson called the Baxter accord the largest agreement ever made between a vendor and a multti-hospital system buying grop. Baxter Chairman Vernon Loucks noted that the contract is expected to extend beyond competitive pricing for supplies. "Clearly, we will save AmHS hospitals money on their purchases from us," Loucks said. "Yet we're committed to going beyond that by working closely together to create efficiencies and savings that we can both share, thus improving the cost effectiveness of health care." Specifically, the agreement calls for AmHS to work with Baxter in a number of areas, such as logistics, materials management, and information systems. Task forces of executives from both organizations will be established to handle the topics. The Baxter agreement is in line with the AmHS strategy of seeking broad corporate relationships. Similar agreements, for example, have been signed with DuPont, for products ranging from film to oil and gas, and with 3M, which supplies AmHS with everything from hospital products to billboard advertising. The accord also fits with the AmHS dual-source policy. One of the group's most recent corporate agreements is with Johnson & Johnson, a $ 750 mil. five-year pact that went into effect in January. The agreement covers all 12 J&J divisions, and includes products such as surgical instruments, would closures, catheters, intraocular lenses and orthopedic devices. AmHS also has corporate vendor contracts with Becton Dickinson, for needles, syringes and blood collection systems; Kendall Colgate; Fuji; and Winthrop Labs. Organized in 1984 via the merger of two buying groups, AmHS has facilities in 43 states, the District of Columbia, and several foreign countries. Its 34 shareholders reported total revenues of more than $ 11 bil. in 1987, and the group says its annual purchasing power exceeds $ 3 bil. Two new shareholders were approved by the board Aug. 9 -- Baptist Health Systems, of Knoxville, Tennessee, formerly part of SunHealth, and Immanuel Medical Center of Omaha, Nebraska.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

PharmaMar Withdraws EU Aplidin Filing After Regulatory Rollercoaster

 

PharmaMar has voluntarily withdrawn its marketing authorization application for Aplidin to treat multiple myeloma in the EU – almost a decade after it first filed the drug for EU approval and following years of court proceedings.

Italy To Reward Locally Conducted R&D In Innovative Medicines Fund Revamp

 

Antibiotics that tackle antimicrobial resistance are to be automatically included in Italy’s Innovative Medicines Fund, which is designed to provide quick access to innovative medicines.

Real-Time Release Of CRLs Is US FDA’s Goal, Agency Leaders Affirm

 

The US FDA says its release of complete response letters for products subsequently approved by the agency is just a first step toward releasing rejection letters when they are issued, assuming legal issues can be resolved.